GlassScriptPhysician profile
K Paul Gerstenberg
NPI 1265430649
$11,853.81
in general payments reported to CMS, 2019-2025
49 companies · $899 in 2025
The $899 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $744 · 2020: $969 · 2021: $2,275 · 2022: $4,502 · 2023: $1,168 · 2024: $1,297 · 2025: $899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,364.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,364.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Midmark Corporation | $3,299.57 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $1,551.92 | 2020-2021 | |
| Novo Nordisk INC | $1,166.68 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $1,150.52 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $667.96 | 2022-2025 | |
| Amarin Pharma, INC. | $446.20 | 2019-2022 | |
| Lilly USA, LLC | $415.03 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $383.05 | 2019-2024 | Farxiga, Breztri |
| Pfizer INC. | $359.45 | 2019-2025 | |
| Glaxosmithkline, LLC. | $172.09 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Antares Pharma, INC. | $166.63 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Astellas Pharma US INC | $162.08 | 2023-2024 | Veozah, Myrbetriq |
| Dexcom, INC. | $159.41 | 2023-2025 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $145.50 | 2024-2025 | Inspire |
| Amgen INC. | $125.86 | 2019-2023 | Repatha |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw K Gerstenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.